BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 37000118)

  • 21. Cardiac imaging techniques for the assessment of immune checkpoint inhibitor-induced cardiotoxicity and their potential clinical applications.
    Li Y; Liu PJ; Zhang ZL; Wang YN
    Am J Cancer Res; 2022; 12(8):3548-3560. PubMed ID: 36119829
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Routine assessment of cardiotoxicity in patients undergoing long-term immune checkpoint inhibitor therapy.
    Tamura Y; Tamura Y; Yamada K; Taniguchi H; Iwasawa J; Yada H; Kawamura A
    Heart Vessels; 2022 Nov; 37(11):1859-1865. PubMed ID: 35633369
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Severe cardiotoxicity in 2 patients with thymoma receiving immune checkpoint inhibitor therapy: A case report.
    Liu S; Ma G; Wang H; Yu G; Chen J; Song W
    Medicine (Baltimore); 2022 Nov; 101(46):e31873. PubMed ID: 36401466
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Circulating biomarkers in the diagnosis and prognosis of immune checkpoint inhibitor-related myocarditis: time for a risk-based approach.
    Murtagh G; deFilippi C; Zhao Q; Barac A
    Front Cardiovasc Med; 2024; 11():1350585. PubMed ID: 38410245
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical characteristics and management of immune checkpoint inhibitor-related cardiotoxicity: A single-center experience.
    Xiao J; Li X; Wang X; Guan Y; Liu H; Liang J; Li Y; Wang B; Wang J
    Front Cardiovasc Med; 2023; 10():1093383. PubMed ID: 37089888
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cardiotoxicity of Immune Checkpoint Inhibitors.
    Zhang L; Jones-O'Connor M; Awadalla M; Zlotoff DA; Thavendiranathan P; Groarke JD; Villani AC; Lyon AR; Neilan TG
    Curr Treat Options Cardiovasc Med; 2019 Jun; 21(7):32. PubMed ID: 31175469
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immune Checkpoint Inhibitor Cardiotoxicity: Understanding Basic Mechanisms and Clinical Characteristics and Finding a Cure.
    Waliany S; Lee D; Witteles RM; Neal JW; Nguyen P; Davis MM; Salem JE; Wu SM; Moslehi JJ; Zhu H
    Annu Rev Pharmacol Toxicol; 2021 Jan; 61():113-134. PubMed ID: 32776859
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An Emergent Form of Cardiotoxicity: Acute Myocarditis Induced by Immune Checkpoint Inhibitors.
    Esposito R; Fedele T; Orefice S; Cuomo V; Prastaro M; Canonico ME; Ilardi F; De Stefano F; Fiorillo L; Santoro C; Esposito G
    Biomolecules; 2021 May; 11(6):. PubMed ID: 34067474
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immune checkpoint inhibitor myocarditis: elucidating the spectrum of disease through endomyocardial biopsy.
    Palaskas NL; Segura A; Lelenwa L; Siddiqui BA; Subudhi SK; Lopez-Mattei J; Durand JB; Deswal A; Zhao B; Maximilian Buja L; Iliescu C
    Eur J Heart Fail; 2021 Oct; 23(10):1725-1735. PubMed ID: 34114291
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Early evaluation of severe immune checkpoint inhibitor-associated myocarditis: a real-world clinical practice.
    Tang X; Li Y; Huang H; Shi R; Shen LT; Qian WL; Yang ZG
    J Cancer Res Clin Oncol; 2023 Sep; 149(11):8345-8357. PubMed ID: 37076643
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Myocarditis in Patients Treated With Immune Checkpoint Inhibitors.
    Mahmood SS; Fradley MG; Cohen JV; Nohria A; Reynolds KL; Heinzerling LM; Sullivan RJ; Damrongwatanasuk R; Chen CL; Gupta D; Kirchberger MC; Awadalla M; Hassan MZO; Moslehi JJ; Shah SP; Ganatra S; Thavendiranathan P; Lawrence DP; Groarke JD; Neilan TG
    J Am Coll Cardiol; 2018 Apr; 71(16):1755-1764. PubMed ID: 29567210
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New Insights into Mechanisms of Immune Checkpoint Inhibitor-Induced Cardiovascular Toxicity.
    Khunger A; Battel L; Wadhawan A; More A; Kapoor A; Agrawal N
    Curr Oncol Rep; 2020 Jun; 22(7):65. PubMed ID: 32514647
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cancer Therapeutics-related Cardiac Dysfunction in Patients Treated With Immune Checkpoint Inhibitors: An Understudied Manifestation.
    Peleg Hasson S; Arnold J; Merdler I; Sivan A; Shamai S; Geva R; Merimsky O; Shachar E; Waissengrin B; Moshkovits Y; Arbel Y; Topilsky Y; Rozenbaum Z; Wolf I; Laufer-Perl M
    J Immunother; 2021 Jun; 44(5):179-184. PubMed ID: 33950028
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Coronary and aortic calcification are associated with cardiovascular events on immune checkpoint inhibitor therapy.
    Schiffer WB; Deych E; Lenihan DJ; Zhang KW
    Int J Cardiol; 2021 Jan; 322():177-182. PubMed ID: 32800916
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prospective screening for myocarditis in cancer patients treated with immune checkpoint inhibitors.
    Furukawa A; Tamura Y; Taniguchi H; Kawamura A; Nagase S; Hayashi A; Tada Y; Sase K; Hatake K
    J Cardiol; 2023 Jan; 81(1):63-67. PubMed ID: 35953399
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cardiotoxicity from immune checkpoint inhibitors.
    Michel L; Rassaf T; Totzeck M
    Int J Cardiol Heart Vasc; 2019 Dec; 25():100420. PubMed ID: 31517036
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neuromuscular and cardiac adverse events associated with immune checkpoint inhibitors: pooled analysis of individual cases from multiple institutions and literature.
    Boutros A; Bottini A; Rossi G; Tanda ET; Spagnolo F; Barletta G; Croce E; Fava P; Parisi A; De Rosa F; Palla M; Marconcini R; Ferrari M; Grandis M; Spallarossa P; Sarocchi M; Arboscello E; Del Mastro L; Lambertini M; Pronzato P; Genova C
    ESMO Open; 2023 Feb; 8(1):100791. PubMed ID: 36791639
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Cardiotoxicity of immune checkpoint inhibitors used in cancer treatment].
    Arangalage D; Pavon AG; Hugelshofer S; Desgraz B; Tzimas G; Delyon J; Muller O; Obeid M; Ribi C; Michielin O; Özdemir BC; Monney P
    Rev Med Suisse; 2020 Jun; 16(696):1165-1168. PubMed ID: 32496706
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characterization of Immune Checkpoint Inhibitor-Related Cardiotoxicity in Lung Cancer Patients From a Rural Setting.
    Moey MYY; Tomdio AN; McCallen JD; Vaughan LM; O'Brien K; Naqash AR; Cherry C; Walker PR; Carabello BA
    JACC CardioOncol; 2020 Sep; 2(3):491-502. PubMed ID: 34396256
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immune checkpoint inhibitor cardiotoxicity: Breaking barriers in the cardiovascular immune landscape.
    Zhu H; Ivanovic M; Nguyen A; Nguyen PK; Wu SM
    J Mol Cell Cardiol; 2021 Nov; 160():121-127. PubMed ID: 34303670
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.